학술논문
Plasma neutrophil gelatinase-associated lipocalin and adverse outcome in critically ill patients with ventilatory support.
Document Type
Article
Author
Source
Subject
*LIPOCALIN-2
*BIOMARKERS
*KIDNEY injuries
*ADULT respiratory distress syndrome
*INTENSIVE care patients
*CHRONIC kidney failure
*DIAGNOSIS
*
*
*
*
*
*
Language
ISSN
0001-5172
Abstract
Objective Plasma neutrophil gelatinase-associated lipocalin (p NGAL) has been introduced as an early and sensitive biomarker of acute kidney injury ( AKI), with an increased risk for renal replacement therapy ( RRT) and adverse outcome in selected critically ill patient groups. Acute respiratory failure is the most common organ dysfunction in critically ill patients with an increased risk for AKI. Accordingly, we hypothesized that p NGAL would independently predict adverse outcome in a heterogeneous group of critically ill adult patients with acute respiratory failure. Design and Setting Prospective, multi-centre study in 25 Finnish intensive care units. Patients and Methods p NGAL was measured from critically ill patients with acute respiratory failure. We evaluated the predictive value of p NGAL for RRT, and hospital and 90-day mortality first separately, second in addition to the Simplified Acute Physiology Score ( SAPS II), and third to RIFLE (Risk, Injury, Failure, Loss, End-Stage Renal Disease) AKI classification. Additionally, we assessed the factors associated with p NGAL by linear regression analysis. Interventions None. Measurements and Main Results We included 369 patients. Median (interquartile range) baseline p NGAL was 169 (92-370) ng/ml. The areas under receiver operating characteristic curves of baseline p NGAL were as follows: 0.733 [95% confidence interval ( CI) 0.656-0.810] for RRT, 0.627 (95% CI 0.561-0.693) for hospital, and 0.582 (95% CI 0.520-0.645) for 90-day mortality. Present infection, baseline creatinine, operative status, and pancreatitis were independently associated with baseline p NGAL. Conclusions Baseline p NGAL gives no additional value into prediction of hospital and 90-day mortality compared with RIFLE or SAPS II, and has only moderate predictive power regarding RRT in critically ill adult patients with acute respiratory failure. [ABSTRACT FROM AUTHOR]